RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Tasly Biopharma of Shanghai has filed a prospectus for a Hong Kong IPO. The transaction, which has been expected for the past year, could raise as much as $1 billion. Tasly Bio is the biologics arm of Tasly Pharma, a TCM company that decided in 2001 to diversify into novel drug development. The company has one launched product, an anti-thrombolytic drug for myocardial infarction, and it is developing 12 other biologic products for cancer, metabolic, gastrointestinal, cardiovascular and autoimmune diseases.
Source: China Biotoday
